Prognostic Value of Hepatocyte Growth Factor, Syndecan-1, and Osteopontin in Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance

Autor: Vlastimil Scudla, Pavla Petrova, Jaroslav Bacovsky, Tomas Pika, Katerina Langova, Jiri Minarik
Rok vydání: 2012
Předmět:
Male
Pathology
Paraproteinemias
lcsh:Medicine
Comorbidity
lcsh:Technology
Gastroenterology
Syndecan 1
hemic and lymphatic diseases
Prevalence
Medicine
Osteopontin
lcsh:Science
Multiple myeloma
Czech Republic
General Environmental Science
Aged
80 and over
biology
Hepatocyte Growth Factor
General Medicine
Middle Aged
Prognosis
Treatment Outcome
Female
Hepatocyte growth factor
medicine.symptom
Multiple Myeloma
Research Article
medicine.drug
Adult
medicine.medical_specialty
Article Subject
Risk Assessment
Sensitivity and Specificity
Asymptomatic
General Biochemistry
Genetics and Molecular Biology
Internal medicine
Remission phase
Biomarkers
Tumor
Humans
Aged
lcsh:T
business.industry
lcsh:R
Significant difference
Reproducibility of Results
medicine.disease
biology.protein
lcsh:Q
Syndecan-1
business
Biomarkers
Monoclonal gammopathy of undetermined significance
Zdroj: The Scientific World Journal
The Scientific World Journal, Vol 2012 (2012)
ISSN: 1537-744X
DOI: 10.1100/2012/356128
Popis: Our aim was to compare serum levels of selected biological parameters in different phases of multiple myeloma (MM) and monoclonal gammopathy of undetermined significance (MGUS) to determine their diagnostic and prognostic potential. A cohort of 234 individuals was assessed for serum levels of hepatocyte growth factor (HGF), syndecan-1/CD138 (SYN), and osteopontin (OPN). The patients with MM ( 𝑁 = 1 5 6 ) were divided into 3 groups: at the time of diagnosis ( 𝑁 = 4 5 ), in relapse/progression ( 𝑁 = 5 6 ), and in remission ( 𝑁 = 5 0 ). The analysis revealed significant differences of all three parameters in comparison of active and remission phase MM. Moreover, the parameters in active myeloma were significantly higher than in MGUS. Within the comparison of active disease (newly diagnosed and relapsing), there was no significant difference. Similar results were in remission phase MM and MGUS. There was no relationship of pretreatment levels of the parameters to therapeutic response. We conclude that serum levels of HGF, OPN, and SYN correspond to the activity of MM and might become useful in differentiation of MGUS, asymptomatic MM, and overt/symptomatic form of MM. The levels of all three parameters behave accordingly with MM activity. Pretreatment measurement without the assessment of their kinetics, however, has no relationship to therapeutic response.
Databáze: OpenAIRE
Externí odkaz: